Neoadjuvant therapy: an emerging concept in oncology.
Neoadjuvant therapy, an adjunctive therapy given before the main therapy, has become an integral part of modem multidisciplinary cancer management. Organized by the primary organ involved by cancer, this review summarizes the outcomes of neoadjuvant therapy for common malignant solid tumors, based on large, randomized, controlled trials. In locally advanced rectal, laryngeal, and breast cancer, neoadjuvant therapy enables organ preservation; however, it does not improve overall survival when compared with definitive treatment followed by adjuvant therapy. In locally advanced bladder and cervical cancer, patients who undergo neoadjuvant therapy before radical surgery appear to have better survival than those receiving definitive therapy alone; however, it is unclear if the neoadjuvant approach will be superior to definitive therapy followed by adjuvant therapy. To date, the survival benefits of neoadjuvant therapy for resectable non-small cell lung, esophageal, gastric, and prostate cancer remains under investigation.
Tanvetyanon
Tawee
T
Division of Hematology/Oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA. ttanve@lumc.edu
Clark
Joseph I
JI
Campbell
Steve C
SC
Lo
Simon S
SS
D005260:Female; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods / Q000706:statistics & numerical data / Q000639:trends; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D011300:Preoperative Care; D016032:Randomized Controlled Trials as Topic